ABBVIE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2023-01-17
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05538585
- Locations
- 🇺🇸
Clinical Pharmacology of Miami /ID# 249531, Miami, Florida, United States
🇺🇸Acpru /Id# 249532, Grayslake, Illinois, United States
A Study to Assess the Pharmacokinetics and Safety of Co-administered Oral Galicaftor, Navocaftor, and ABBV-576 in Healthy Adults for the Treatment of Cystic Fibrosis
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 24
- Registration Number
- NCT05530278
- Locations
- 🇺🇸
Anaheim Clinical Trials LLC /ID# 248824, Anaheim, California, United States
🇺🇸Clinical Pharmacology of Miami /ID# 248823, Miami, Florida, United States
🇺🇸PPD Clinical Research Unit -Las Vegas /ID# 248853, Las Vegas, Nevada, United States
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
- Conditions
- Endometrial CancerHigh Grade Serous Adenocarcinoma of OvaryPrimary Peritoneal CarcinomaFallopian Tube CancerCervical Cancer
- Interventions
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 423
- Registration Number
- NCT05527184
- Locations
- 🇺🇸
University of Alabama at Birmingham /ID# 269045, Birmingham, Alabama, United States
🇺🇸City of Hope National Medical Center /ID# 269036, Duarte, California, United States
🇺🇸Moores Cancer Center /ID# 269040, La Jolla, California, United States
A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 9
- Registration Number
- NCT05513703
- Locations
- 🇫🇷
Hospices Civils de Lyon (HCL) - Hopital Louis Pradel /ID# 246267, Bron, Rhone, France
🇦🇺Monash Medical Centre /ID# 247679, Clayton, Victoria, Australia
🇫🇷CHU Lille - Hôpital Albert Calmette /ID# 246263, Lille, Hauts-de-France, France
A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)
- Conditions
- Diffuse Large B-Cell LymphomaChronic Lymphocytic LeukemiaFollicular Lymphoma
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 154
- Registration Number
- NCT05512390
- Locations
- 🇺🇸
University of Arizona Cancer Center - Tucson /ID# 247752, Tucson, Arizona, United States
🇺🇸Sylvester Comprehensive Cancer Center - University of Miami /ID# 247232, Miami, Florida, United States
🇺🇸Allina Health System /ID# 251782, Minneapolis, Minnesota, United States
A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 461
- Registration Number
- NCT05507580
- Locations
- 🇮🇹
Azienda Ospedaliera di Perugia /ID# 246632, Perugia, Umbria, Italy
🇨🇦Dermatology Research Institute - Blackfoot Trail /ID# 246703, Calgary, Alberta, Canada
🇧🇬Medical center Cordis /ID# 253310, Pleven, Bulgaria
A Study to Evaluate Sequential Administration of AGN-151586 and OnabotulinumtoxinA (BOTOX) Injections in Adult Participants for Treatment of Glabellar Lines
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2023-06-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 90
- Registration Number
- NCT05496335
- Locations
- 🇺🇸
The Eye Research Foundation /ID# 244430, Newport Beach, California, United States
🇺🇸DeNova Research /ID# 244421, Chicago, Illinois, United States
🇺🇸Bellaire Dermatology Associates /ID# 244428, Bellaire, Texas, United States
Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 400
- Registration Number
- NCT05496348
- Locations
- 🇩🇪
Praxis Dr. Weber /ID# 256099, Jena, Germany
🇩🇪Prof-med-stud.de /ID# 255419, Munich, Germany
🇩🇪Dr. Schirin-Sokhan /ID# 259158, Würselen, Germany
An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 785
- Registration Number
- NCT05494606
- Locations
- 🇮🇱
Tel Aviv Sourasky Medical Center /ID# 250562, Tel Aviv, Tel-Aviv, Israel
🇮🇱Rabin Medical Center /ID# 249474, Petah Tikva, Israel
🇮🇹Ente Ospedaliero Specializzato in Gastroenterologia Saverio de Bellis - IRCCS /ID# 261600, Castellana Grotte, Bari, Italy
A Single Ascending Oral Dose Study of SDI-118 in Healthy Male Subjects Including an Assessment of Receptor Occupancy and Food Effect
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2022-08-03
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 32
- Registration Number
- NCT05486195
- Locations
- 🇧🇪
Centre for Clinical Pharmacology, UZ Leuven, Leuven, Belgium